by Cleveland Clinic Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0 New Cleveland Clinic research has found that drugs originally designed to help treat Alzheimer’s disease may hold promise for glioblastoma, the most common and lethal type of primary brain tumor. The findings were published in Nature Cancer. A class of drugs called BACE1 inhibitors were once among...
by Thomas Crow, Particle The numbers of Australians with dementia are increasing each year (largely because of population growth). Credit: Australian Institute of Health and Welfare A team of WA researchers may have discovered a cheap, revolutionary treatment for Alzheimer’s disease—and the key is a body part you may not expect. Dementia is the second leading...
by Emily Caldwell, The Ohio State University We know about circadian regulation of sleep, but new research in a mouse model of Alzheimer’s disease suggests beta-amyloid buildup in the brain could also contribute to deficits in circadian regulation of learning and memory early in the disease process. Credit: Shutterstock.com Circadian dysfunction linked to Alzheimer’s disease is...
Studying the complex causes of Alzheimer’s disease, and how to treat and prevent this condition, is like solving a many-piece puzzle, with scientists each tackling a small section, unsure of how it might fit into the larger picture. Now, researchers at Gladstone Institutes have determined how a handful of previously unconnected puzzle sections fit together....
BRIGHAM AND WOMEN’S HOSPITAL Brigham and Women’s Hospital is set to begin a clinical trial that will test the safety and efficacy of a new vaccine delivered nasally intended to prevent and slow the progression of Alzheimer’s disease (AD). The trial represents the culmination of nearly 20 years of research led by Howard L. Weiner,...
Nov. 5, 2021 Losing memory is a hallmark of Alzheimer’s, a symptom of the disease that depletes a patient’s quality of life. Improving memory and slowing cognitive changes caused by the disease is an ongoing challenge for researchers seeking to develop novel therapies. In a newly published paper in Frontiers in Neuroscience, researchers at the Del Monte...
by Indiana University School of Medicine Credit: CC0 Public Domain When immune cells move throughout the brain, they act as the first line of defense against viruses, toxic materials, and damaged neurons, rushing over to clear out them. Researchers at Indiana University School of Medicine have been investigating how these immune cells in the brain—microglia—relate...
INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB BARCELONA) IMAGE: DESCRIPTION OF THE EXPERIMENTAL FLOWCHART CREDIT: IRB BARCELONA Barcelona, 27 October 2021,- Alzheimer’s disease is the most common cause of dementia in Western societies and it is estimated that 24 million people worldwide have this condition. ICREA researcher Dr. Patrick Aloy, head of the Structural Bioinformatics and Network...
by Sarah C.p. Williams, Gladstone Institutes A new study by Gladstone scientists suggests that certain anti-epileptic or tau-reducing treatments could be promising for people in the early stages of Alzheimer’s disease. Credit: Michael Short / Gladstone Institutes Studying the complex causes of Alzheimer’s disease, and how to treat and prevent this condition, is like solving a...
Pauline Anderson A new noninvasive procedure is safe and effective for treating patients with mild Alzheimer’s disease (AD), new research suggests. Clinicians monitor a trial patient with AD undergoing low-intensity focused ultrasound. The approach uses MRI-guided low-intensity focused ultrasound (FUS) and injected microbubbles to temporarily open the blood-brain barrier (BBB). In a small group of patients, the...
